Last week’s significant research news included positive new Phase III data on Tezspire in nasal polyps from Amgen and ...

Jazz Pharmaceuticals’ acquisition of Chimerix brings a drug that could become the first approved therapy for a rare and ...

Jazz Pharma to buy biopharmaceutical company, Chimerix for approximately $935 million: Dublin Friday, March 7, 2025, 14:00 Hrs [IST] Jazz Pharmaceuticals plc, a global biopharmace ...

Mergers and acquisitions grabbed the spotlight in the biotech sector this week after Jazz Pharmaceuticals announced an ...

AbbVie made a $350 million upfront payment to Gubra for rights to the drug, called GUB014295. Gubra is also eligible to receive another $1.9 billion if certain development and sales milestones are met ...

Flourish Research, a multi-site clinical trials company based in Apex, has acquired a California clinical research facility.

Mergers and acquisitions grabbed the spotlight in the biotech sector this week after Jazz Pharmaceuticals JAZZ announced an agreement to acquire Chimerix CMRX. Meanwhile, other pipeline and regulatory ...

In a deal worth approximately $935m, Jazz Pharmaceuticals is set to acquire Chimerix, a biotechnology company developing ...

"We are currently engaging with market participants," a spokesperson for South Africa's Competition Commission told Reuters, declining to provide details. USAID cuts put tuberculosis response in peril ...

Ireland-headquartered Jazz Pharmaceuticals has entered into a definitive agreement to acquire US biopharma company Chimerix ...

Chimerix’s lead clinical pipeline candidate is dordaviprone, a first-in-class small molecule treatment designed to selectively target the mitochondrial protease ClpP and dopamine receptor D2 (DRD2).

Jazz Pharmaceuticals plc is buying Chimerix Inc. for $8.55 a share in cash, bringing the deal in at about $935 million. Jazz ...